dedicated and visionary entrepreneurs committed to make a difference.
Who we are
Pioneers for 20 years
The Avesina Group was founded more than 20 years ago as a pioneer within the field of healthcare services. With a strong belief in leveraging technology to strengthen the patients’ individual choices, increase quality and patient safety, Avesina was one if the first within the industry to digitalize its services. By doing so the group was able to implement a holistic perspective throughout the whole healthcare chain, increase accessibility and profitability to boost rapid growth.
Equality, inclusion and personal development formed the core of the company’s culture which fostered creativity and a unified vision to improve the healthcare system. During the 20 years that Shori Zand built Avesina together with her sons Emad and Daniel, who joined the family business in the expansion phase, Avesina drove change, national healthcare reforms and implemented new innovative solutions that became golden standard within the industry.
Today the Avesina Group is an investment firm with a clear mission – to drive change trough innovation, by increasing customer utility and satisfaction, as well as creating a positive societal impact.
With a strong track record as entrepreneurs building successful companies, Avesina is now dedicated to support and enable visionary entrepreneurs committed to build businesses which make a difference. Today the portfolio includes companies within the healthcare, biotech and medtech sectors.
Avesina has a diversified holding strategy that includes listed and non-listed equities, bonds, and other investment instruments.
In the media
The story of Avesina
The Avesina Health Care Group was founded in 2000 with a clear vision to individualize care and care services according to patients’ needs and to integrate technology in healthcare services to achieve an innovative, efficient and suitable care process.
Already in 2000, Avesina advocated a freedom of choice system to give people the right to choose their care provider. A democratic right with the goal to create accessibility, security and patient satisfaction.
Innovative thinking, dedication and forward-looking work enabled Avesina to in a very short time, position itself as a strong player in the market and win several major government contracts. Avesina took an active role in and became a strong voice in the industry striving for an freer market with healthy competition, increased diversity amongst healthcare providers and for equality in the workplace.
2000Establishment of first clinic in the County of Östergötland. The ambition is to create a new type of clinic with a home-style environment were the patients’ choice is in focus.
2003Avesina expands and starts a gynecology clinic in the County of Blekinge.
2006Avesina Group is firmed as the company moves into new verticals such as elderly care, diagnostics, primary care, specialist care and hearing.
2006Avesina wins a large contract and expands from 7 000 patients to 40 000 in one year.
2008-9Winning three combined Government contracts, Avesina becomes the largest provider of mammography screening as well as in hearing in Sweden.
2011The Avesina Group exits its investments in diagnostics, elderly care and gynecology. The Group is restructured into an Asset management branch that trades in listed equities and bonds, and an Investment branch focused on building innovative
2015Avesina Hearing is sold to the Danish William Demant Group. The transformation of the Avesina Group to work exclusively with investments and company building starts now.
A family-owned company
Avesina Health care was a family owned and a family run company where Shori Zand and her sons Daniel and Emad were active and involved in various leading positions in the company’s growth and development. The company under the leadership of the family with a strong corporate culture was characterized by diversity, gender equality and quality awareness, grew from 2 employees to 1400 employees and from one business to a group with 6 companies with a turnover of about half a billion. The family made their total exit from the market in 2015 to change course and this time as an investment company with an interest in Medtech, life science and welfare focused companies.